Pfizer Vaccine Efficiency Is Low Against Hospitalisation In South Africa

Pfizer Vaccine Efficiency Is Low Against Hospitalisation In South Africa
SHARE

The efficiency of the Pfizer vaccine in South Africa has been recently analyzed in a new study, and the results are not that optimistic. Check out the following reports about the issue from the Reuters press agency. 

According to the latest reports coming from the Reuters press agency, it’s been reported that Pfizer-BioNTech’s covid19 vaccine has been less effective in South Africa at keeping people infected with the virus out of hospital since the Omicron variant emerged last month.

This is what a real-world study published on Tuesday showed.

Pfizer has been making headlines all over the place during 2021 due to the vaccines that the company rolled out to fight the novel coronavirus and the terrible disease that it can trigger.

Pfizer covid pill efficiency revealed 

More than that, Pfizer also rolled out a more or less viable pill – this remains to be seen, and more studies are currently undergoing these days. 

Earlier today, we revealed that CNBC notes that Pfizer said the final analysis of its antiviral Covid-19 pill still showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients.

More than that, it’s been revealed that recent lab data suggests the fact that the drug retains its effectiveness against the fast-spreading Omicron variant of the coronavirus.

Source: pixabay.com

It’s also been revealed that last month Pfizer said the oral medicine was “around 89% effective in preventing hospitalizations or deaths when compared to placebo based on interim results in around 1,200 people.”

The data disclosed on Tuesday includes more than 1,000 people.

CNBC also notes something pretty disturbing:

“Nobody in the trial who got the Pfizer treatment died, compared with 12 deaths among placebo recipients.”

The same publication also notes the following: 

“The Pfizer pills are taken with the older antiviral ritonavir every 12 hours for five days beginning shortly after onset of symptoms. If authorized, the treatment will be sold as Paxlovid.”

Stay tuned for more news about the novel coronavirus and the disease that this new virus can trigger. 


SHARE
Rada Mateescu

Passionate about subjects from the science and health-related areas, Rada has been blogging for about ten years and at Health Thoroughfare, she's covering the latest news on these niches.

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.